Abstract: Objective To observe the clinical efficacy and adverse reaction of secukinumab with herbal fumigation in the treatment of patients with moderate to severe plaque psoriasis. Methods A total of 68 patients with moderate to severe plaque psoriasis were randomly divided into two groups by digital table method, with 34 cases in each group.The control group was treated with self-made traditional Chinese medicine Yangxue Runzao Qufeng soup and tacrolimus ointment, and the treatment group was received treatment with 300 mg of Sikuximab on the basis of the control group. Both groups will require continuous observation for at least 24 weeks. The efficacy was assessed by the changes of Psoriasis Area and Severity Index （PASI) , Body Surface Area (BSA),and Dermatology Life Quality Index(DLQI) before treatment and at weeks 4, 12, and 24. The adverse drug reaction was also analyzed. Results After 24 weeks of treatment, no patient exit from the study due to drug intolerance or adverse drug reactions. After weeks 4, 12 and 24, there were significant differences in PASI score, BSA score and DLQI score in the treatment group compared with the control group （P <0.05); Except that there were no significant difference in PASI 100 response rate at week 4 （P =0.063), PASI 75/90/100 response rates were all statistically significant （P<0.05); and DLQI 0/1 response rates were also significant differences （P<0.001). Conclusion Secukinumab with herbal fumigation in the treatment of patients with moderate to severe plaque psoriasis can obtain high PASI 75/90/100 and DLQI 0/1 response rates and has a relatively high safety profile.

Key words: moderate to severe plaque psoriasis, secukinumab, herbal fumigation, adverse reaction